C6461013 - An Interventional Open-label Phase 1b/2 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 as Monotherapy and Combination Therapy in Adult Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma

Condition studied

Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma

Investigational medicinal product(s)

Every trial of PF-08634404 and Ipilimumab across our registers →

Eligibility

Primary endpoint

Phase 1b (Safety Run-In): AEs as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention., DLTs, Phase 2 (Dose Optimization/Expansion): Confirmed ORR per RECIST 1.1 by investigator., AEs as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention.

Endpoint detail

Phase 1b (Safety Run-In): Confirmed ORR per RECIST 1.1 by investigator, DOR per RECIST 1.1 by investigator, PFS per RECIST 1.1 by investigator, OS, Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing., Predose and/or postdose concentrations of PF-08634404, Incidence of ADA against PF-08634404, Phase 2 (Dose Optimization/Expansion): DOR per RECIST 1.1 by investigator, PFS per RECIST 1.1 by investigator, OS, Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing., Predose and/or postdose concentrations of PF-08634404., Incidence of ADA against PF-08634404.